Domicile
Reels
Groupes
Pages
Plus
Groupes Pages Evènements Blogs Financement
Se connecter S’enregistrer
Mode nuit
Autologous vs. Allogeneic: The CAR T Manufacturing Race
The promise of CAR T therapy is constrained by a manufacturing challenge: creating personalized treatments at scale is complex, time-consuming, and expensive. Autologous therapy—using the patient's own cells—requires a bespoke manufacturing process for each patient, with vein-to-vein times that can delay treatment. Allogeneic therapy—using donor cells—offers the...
0 Commentaires ·0 Parts ·21 Vue ·0 Aperçu
Connectez-vous pour aimer, partager et commenter!